Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett’s Esophagus With a Minimally Invasive Cell Sampling Device  Curtis R. Heberle, Amir-Houshang Omidvari, Ayman Ali, Sonja Kroep, Chung Yin Kong, John M. Inadomi, Joel H. Rubenstein, Angela C. Tramontano, Emily C. Dowling, William D. Hazelton, E. Georg Luebeck, Iris Lansdorp-Vogelaar, Chin Hur  Clinical Gastroenterology and Hepatology  Volume 15, Issue 9, Pages 1397-1404.e7 (September 2017) DOI: 10.1016/j.cgh.2017.02.017 Copyright © 2017 AGA Institute Terms and Conditions

Figure 1 Cost/benefit curves for the (A) MGH (blue) and (B) Erasmus/UW (green) models. All numbers are reported per 1000 GERD patients at the start of screening. NH, natural history. Clinical Gastroenterology and Hepatology 2017 15, 1397-1404.e7DOI: (10.1016/j.cgh.2017.02.017) Copyright © 2017 AGA Institute Terms and Conditions

Figure 2 Sensitivity analysis of the Cytosponge cost performed with the MGH and Erasmus/UW models. ICERs corresponding to the efficiency frontier are shown at each point. Clinical Gastroenterology and Hepatology 2017 15, 1397-1404.e7DOI: (10.1016/j.cgh.2017.02.017) Copyright © 2017 AGA Institute Terms and Conditions

Supplementary Figure 1 Proportion of PSA runs favoring each strategy by willingness-to-pay threshold, assuming a fixed willingness-to-pay ratio of $100,000 (MGH model). Clinical Gastroenterology and Hepatology 2017 15, 1397-1404.e7DOI: (10.1016/j.cgh.2017.02.017) Copyright © 2017 AGA Institute Terms and Conditions

Supplementary Figure 2 Proportion of PSA runs favoring each strategy by willingness-to-pay threshold, assuming a fixed Cytosponge cost of $182 (MGH model). Clinical Gastroenterology and Hepatology 2017 15, 1397-1404.e7DOI: (10.1016/j.cgh.2017.02.017) Copyright © 2017 AGA Institute Terms and Conditions

Supplementary Figure 3 Indirect cost adjustment and base-case results (MGH model). Clinical Gastroenterology and Hepatology 2017 15, 1397-1404.e7DOI: (10.1016/j.cgh.2017.02.017) Copyright © 2017 AGA Institute Terms and Conditions

Supplementary Figure 4 Indirect cost and base case results of the Erasmus/UW model. Clinical Gastroenterology and Hepatology 2017 15, 1397-1404.e7DOI: (10.1016/j.cgh.2017.02.017) Copyright © 2017 AGA Institute Terms and Conditions